Chargement en cours...

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis

Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing–remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patien...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:CNS Drugs
Auteurs principaux: Chan, Andrew, de Seze, Jérôme, Comabella, Manuel
Format: Artigo
Langue:Inglês
Publié: Springer International Publishing 2016
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4733135/
https://ncbi.nlm.nih.gov/pubmed/26758290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-015-0299-y
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!